Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification

Int J Cancer. 2001 Mar 1;91(5):680-6. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1114>;2-r.


We have studied the occurrence and association of 11q deletions with other chromosomal imbalances in Stage 4 neuroblastomas. To this purpose we have performed comparative genomic hybridization (CGH) analysis on 50 Stage 4 neuroblastomas and these data were analyzed together with those from 33 previously published cases. We observed a high incidence of 11q deletion in Stage 4 neuroblastoma without MYCN amplification (59%) whereas 11q loss was only observed in 15% of neuroblastomas with MYCN-amplification (p = 0.0002) or 11% of cases with 1p deletion detected by CGH (p = 0.0001). In addition, 11q loss showed significant positive correlation with 3p loss (p = 0.0002). Event-free survival was poor and not significantly different for patients with or without 11q deletion. Our study provides further evidence that Stage 4 neuroblastomas with 11q deletions represent a distinct genetic subgroup that typically shows no MYCN-amplification nor 1p deletion. Moreover, it shows that neuroblastomas with 11q deletion also often present 3p deletion. This genetic subgroup shows a similar poor prognosis as MYCN amplified 4 neuroblastomas.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Chromosome Aberrations
  • Chromosome Deletion*
  • Chromosomes, Human, Pair 1
  • Chromosomes, Human, Pair 11*
  • Chromosomes, Human, Pair 3
  • Disease-Free Survival
  • Female
  • Genome, Human*
  • Humans
  • In Situ Hybridization, Fluorescence
  • Infant
  • Male
  • Models, Genetic
  • Multicenter Studies as Topic
  • Mutation
  • Neoplasm Metastasis
  • Neuroblastoma / diagnosis
  • Neuroblastoma / genetics*
  • Neuroblastoma / mortality
  • Nucleic Acid Hybridization*
  • Prognosis
  • Time Factors
  • Tumor Cells, Cultured